PHARMOS CORP NEW
PARS
PARS was delisted on the 12th of March, 2009.
0 hedge funds and large institutions have $0 invested in PHARMOS CORP NEW in 2020 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $12 → $0 (-$12)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWA
Arkadios Wealth Advisors
Atlanta,
Georgia
|
-$12 |
PARS Hedge Fund Activity: Q3 2020 in Review
0 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in PHARMOS CORP NEW (PARS) for Q3 2020, worth a combined $0 — down 100% from $12 a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of PARS and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Arkadios Wealth Advisors, exiting entirely with an estimated $12 sold.
- 0 institutional investors held PHARMOS CORP NEW (PARS) as of Q3 2020, down from 1 in Q2 2020.
- Funds reported $0 of PHARMOS CORP NEW stock for Q3 2020, down 100% quarter-over-quarter.
- 0 funds opened new PHARMOS CORP NEW positions in Q3 2020 and 1 closed out, a net change of -1 holder.
- The largest PHARMOS CORP NEW seller in Q3 2020 was Arkadios Wealth Advisors, an estimated $12 sold.
Based on aggregated 13F filings for Q3 2020.